AU1521000A - Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye - Google Patents

Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye

Info

Publication number
AU1521000A
AU1521000A AU15210/00A AU1521000A AU1521000A AU 1521000 A AU1521000 A AU 1521000A AU 15210/00 A AU15210/00 A AU 15210/00A AU 1521000 A AU1521000 A AU 1521000A AU 1521000 A AU1521000 A AU 1521000A
Authority
AU
Australia
Prior art keywords
stnfri
prophylaxis
disorders
eye
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15210/00A
Inventor
M. Reza Dana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Publication of AU1521000A publication Critical patent/AU1521000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU15210/00A 1998-11-06 1999-11-05 Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye Abandoned AU1521000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10735198P 1998-11-06 1998-11-06
US60107351 1998-11-06
PCT/US1999/026262 WO2000027421A2 (en) 1998-11-06 1999-11-05 LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE

Publications (1)

Publication Number Publication Date
AU1521000A true AU1521000A (en) 2000-05-29

Family

ID=22316208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15210/00A Abandoned AU1521000A (en) 1998-11-06 1999-11-05 Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye

Country Status (2)

Country Link
AU (1) AU1521000A (en)
WO (1) WO2000027421A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
PT1755674E (en) 2004-05-14 2015-02-05 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
WO2007103134A2 (en) 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MX2008014260A (en) * 2006-05-19 2008-11-26 Alcon Res Ltd Rnai-mediated inhibition of tumor necrosis factor î±-related conditions.
WO2009052140A1 (en) * 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
JP5508398B2 (en) 2008-05-07 2014-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Therapeutic supplementation and enhancement of ocular surface lubrication
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
KR101514238B1 (en) 2012-06-21 2015-04-28 한올바이오파마주식회사 A novel use of modified human tumor necrosis factor receptor-1
JP2016531910A (en) 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treatment of transplant rejection by administration of complement inhibitors to pre-transplant organs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513754A (en) * 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Combination therapy using TNF binding proteins for treating TNF-mediated diseases

Also Published As

Publication number Publication date
WO2000027421A3 (en) 2000-10-05
WO2000027421A2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
AU1633400A (en) Systems and methods for electrosurgical treatment of vascular disorders
WO2002067810A3 (en) Adjustable bone protheses and related methods
AU5654094A (en) Application of riluzole in the treatment of neurological lesions related to traumatic injuries
NO992755D0 (en) Prosthesis of the tendon's retina for the treatment of presbyopia and other disorders of the eyes
WO2000038663A3 (en) Ep4 receptor agonists for treatment of dry eye
PL352229A1 (en) Prosthesis of sclera for treatment of presbyopia and other sight disorders
AU4340199A (en) Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
AU6391700A (en) Vascular device for emboli, thrombus and foreign body removal and methods of use
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
IL158775A0 (en) Use of an antioxidant for treating and or preventing surface ocular disorders
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU2002307430A1 (en) Method and system for photodisruption of tissue of the eye
AU1521000A (en) Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
EP1383529A4 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin 4 (t 4), analogues, isoforms and other derivatives
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU3965497A (en) Methods of treatment of eye trauma and disorders
AU9065291A (en) Use of angiotensin ii receptor antagonists in the treatment of macular degeneration
AU2182800A (en) Use of inhibitors of gag synthesis for the treatment of corneal haze
PL368565A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
AU2434297A (en) The use of 5-ht1b/1d agonists to treat ocular pain
AU2002361516A1 (en) Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase